LPT 111111- A Single-Arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE) and Lapatinib (TYKERB) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 12 Feb 2018 Status changed from active, no longer recruiting to completed.
- 10 Jan 2018 Planned End Date changed from 1 Dec 2017 to 31 Dec 2018.
- 07 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.